Multiple sclerosis patients under treatment with interferon β1-a or ocrelizumab exhibit different T and B cell responses to SARS-CoV-2 vaccine.

Liotti A, Maniscalco G T, Ferrara A L, Mazzone V, Dehbozorgi M, Szabó A, Belardo M, Marcogiuseppe D, De Martino A, Di Battista M E, et al.

Front Immunol. 2026; 17:1773417. PMID: 42382741. Abstract